Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.0K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

966
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
966
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

402
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
402
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.0K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

369
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
369

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
Same author

Sex Differences in LVAD Therapy: From Diagnosis to Destination.

Current heart failure reports·2026
Same author

Biomarkers and genetic determinants of cardiac sarcoidosis: current status, the unmet needs and future perspectives.

Frontiers in cardiovascular medicine·2026
Same author

Aortic Root Thrombosis With Multivessel Coronary Embolism Following Left Ventricular Assist Device Implantation.

JACC. Case reports·2026
Same author

CT-based cannula position predicts neurological risk in patients with HeartMate 3 LVAD.

JHLT open·2026
Same author

Left ventricular transmural pressure: A predictor of left ventricle unloading in continuous flow left ventricular assist devices.

The International journal of artificial organs·2025
Same journal

Contemporary medical management of left ventricular assist device patients: integrating sex-specific perspectives.

Current opinion in cardiology·2026
Same journal

Viability testing for guiding revascularization in ischemic cardiomyopathy.

Current opinion in cardiology·2026
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: Feb 16, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K

Recent advances in heart failure.

Mahwash Kassi1, Bashar Hannawi2, Barry Trachtenberg2

  • 1Mayo Clinic, Rochester, Minnesota.

Current Opinion in Cardiology
|January 5, 2018
PubMed
Summary
This summary is machine-generated.

New heart failure drugs and devices offer improved outcomes for reduced ejection fraction (HFrEF), but treatments for preserved ejection fraction (HFpEF) focus on symptom relief. Careful review of recent literature is crucial for effective patient management.

More Related Videos

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 16, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

2.0K
Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

13.4K
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

1.2K

Area of Science:

  • Cardiology
  • Internal Medicine
  • Pharmacology

Background:

  • Acute heart failure management remains challenging with limited therapeutic benefits.
  • Cardiac resynchronization therapy is standard, but its timing and need for defibrillators are debated.
  • Advances in drug and device therapy are emerging for heart failure treatment.

Purpose of the Study:

  • To review recent pivotal studies in heart failure with reduced ejection fraction (HFrEF).
  • To update on critical recent research in heart failure with preserved ejection fraction (HFpEF).

Main Methods:

  • Review of recent clinical trials and therapeutic advancements.
  • Analysis of drug efficacy and device performance data.
  • Evaluation of management strategies for HFrEF and HFpEF.

Main Results:

  • HFrEF benefits from new drugs like ivabradine and ARNIs.
  • The HeartMate 3 LVAD shows promise but has challenges like stroke and RV failure.
  • HFpEF studies show limited outcome improvements; management focuses on lifestyle and symptoms.

Conclusions:

  • Newer therapies and devices show success, but some offer no benefit or cause harm.
  • Effective heart failure management requires careful consideration of the latest evidence.
  • Ongoing research is vital for advancing heart failure care.